Latest Immtech Pharm Inc (IMMP) Headlines
Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections - Pipeline Review, H2 2013 Research Report
M2 - Wed Feb 05, 2:35AM CST
Research and Markets (http://www.researchandmarkets.com/research/kbm7xt/methicillinsuscep) has announced the addition of the "Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections - Pipeline Review, H2 2013" report to their offering. 'Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections. Scope - A snapshot of the global therapeutic scenario for Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections. - A review of the Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Some Key Topics Covered: Introduction Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections Overview Therapeutics Development Pipeline Products for Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections - Overview Pipeline Products for Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections - Comparative Analysis brilacidin - Drug Profile LTX-109 - Drug Profile PGC Anti-MRSA - Drug Profile IMV-0123 - Drug Profile SM-295291 - Drug Profile SM-369926 - Drug Profile ASN-100 - Drug Profile Antibiotic Program - Drug Profile Drugs for Bacterial Infections - Drug Profile Human Cathelicidin LL-37 Derivatives - Drug Profile Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections - Recent Pipeline Updates Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections - Dormant Projects Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections - Discontinued Products Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections - Product Development Milestones Companies Mentioned Dainippon Sumitomo Pharma Co., Ltd. Immtech Pharmaceuticals, Inc. Cellceutix Corporation Lytix Biopharma AS PharmaIN Corporation ImmuVen, Inc. Arsanis Biosciences GmbH For more information visit http://www.researchandmarkets.com/research/kb...llinsuscep About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Market Research: Gram-Positive Bacterial Infections - Pipeline Review, H2 2013
M2 - Wed Nov 06, 2:55AM CST
Research and Markets (http://www.researchandmarkets.com/research/lxgdwn/grampositive) has announced the addition of the "Gram-Positive Bacterial Infections - Pipeline Review, H2 2013" report to their offering. 'Gram-Positive Bacterial Infections - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Gram-Positive Bacterial Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Gram-Positive Bacterial Infections. Scope - A snapshot of the global therapeutic scenario for Gram-Positive Bacterial Infections. - A review of the Gram-Positive Bacterial Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Gram-Positive Bacterial Infections pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Rib-X Pharmaceuticals, Inc. Aphios Corporation BioMarin Pharmaceutical Inc. Alchemia Limited Immtech Pharmaceuticals, Inc. Basilea Pharmaceutica Ltd. Oragenics, Inc. Dongwha Pharm Co., Ltd. Theravance, Inc. Phynova Group Ltd Novabiotics Ltd Priaxon AG ConjuGon, Inc. MicuRx Pharmaceuticals, Inc. AiCuris GmbH & Co. KG Destiny Pharma Ltd. Atox Bio Inc. Microbiotix, Inc. Cellceutix Corporation KYORIN Pharmaceutical Co., Ltd. Lytix Biopharma AS TAXIS Pharmaceuticals, Inc. Aureogen Biosciences, Inc. Cantab Biopharmaceuticals Limited For more information visit http://www.researchandmarkets.com/research/lx...ampositive About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline Review, H2 2013
M2 - Tue Oct 15, 9:04AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8fv3sr/methicillinresist) has announced the addition of the "Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline Review, H2 2013" report to their offering. 'Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections. Scope - A snapshot of the global therapeutic scenario for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections. - A review of the Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Genentech, Inc. Targeted Genetics Corporation Takeda Pharmaceutical Company Limited Piramal Healthcare Limited Rib-X Pharmaceuticals, Inc. Aphios Corporation BioMarin Pharmaceutical Inc. Cubist Pharmaceuticals, Inc. Wockhardt Limited Paratek Pharmaceuticals, Inc. Alchemia Limited Helix BioMedix, Inc. Immtech Pharmaceuticals, Inc. Lorus Therapeutics Inc Basilea Pharmaceutica Ltd. NovaBay Pharmaceuticals, Inc. Oragenics, Inc. MorphoSys AG Theravance, Inc. Galapagos NV CrystalGenomics, Inc. Phynova Group Ltd Microbio Co., Ltd. and many more... For more information visit http://www.researchandmarkets.com/research/8f...llinresist About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Malaria - Pipeline Review, H2 2013
M2 - Wed Oct 09, 6:16AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nj95jg/malaria) has announced the addition of the "Malaria - Pipeline Review, H2 2013" report to their offering. 'Malaria - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Malaria, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Malaria. Scope - A snapshot of the global therapeutic scenario for Malaria. - A review of the Malaria products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Malaria pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Malaria. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Malaria pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned Genzyme Corporation Sanofi-Aventis AstraZeneca PLC GlaxoSmithKline plc Inovio Biomedical Corporation GenVec, Inc. Novartis AG Actelion Ltd Chong Kun Dang Pharmaceutical Eisai Co., Ltd. Pfizer Inc. Ranbaxy Laboratories Limited Aduro BioTech CEL-SCI Corporation Crucell N.V. Hollis-Eden Pharmaceuticals, Inc. Immtech Pharmaceuticals, Inc. Mymetics Corporation Patrys Limited BioCryst Pharmaceuticals, Inc. IPCA Laboratories Limited Lipoxen PLC Raptor Pharmaceuticals Corp. Affitech A/S and many more... For more information visit http://www.researchandmarkets.com/research/nj95jg/malaria About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Enterococcus Faecium Infections - Pipeline Review, H2 2012
M2 - Thu Aug 01, 6:09AM CDT
Research and Markets (http://www.researchandmarkets.com/research/k929nz/enterococcus) has announced the addition of the "Enterococcus Faecium Infections - Pipeline Review, H2 2012" report to their offering. This research provides an overview of the Enterococcus Faecium Infections therapeutic pipeline. I also provides information on the therapeutic development for Enterococcus Faecium Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Enterococcus Faecium Infections. The information is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Scope - A snapshot of the global therapeutic scenario for Enterococcus Faecium Infections. - A review of the Enterococcus Faecium Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Enterococcus Faecium Infections pipeline on the basis of route of administration and molecule type. - Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress. Key Topics Covered: List of Tables List of Figures Introduction Report Coverage Enterococcus Faecium Infections Overview Therapeutics Development An Overview of Pipeline Products for Enterococcus Faecium Infections Companies Involved in Enterococcus Faecium Infections Therapeutics Development Drug Profiles with Product Descriptions and Mechanisms of Action Featured News & Press Releases Appendix Companies Mentioned: - Aquapharm Biodiscovery Limited - Ceragenix Pharmaceuticals - Immtech Pharmaceuticals - Lorus Therapeutics - MerLion Pharmaceuticals - MicuRx Pharmaceuticals, Inc - Nabi Biopharmaceuticals - Oragenics, Inc - Paratek Pharmaceuticals - Piramal Healthcare Limited - Trius Therapeutics, Inc - Wockhardt Limited For more information visit http://www.researchandmarkets.com/research/k9...terococcus
Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections - Pipeline Review, H1 2013
M2 - Wed Jun 19, 10:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5dnrjr/methicillinsuscep) has announced the addition of the "Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections - Pipeline Review, H1 2013" report to their offering. 'Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections. M Scope - A snapshot of the global therapeutic scenario for Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections. - A review of the Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections products under development by companies and unive
Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections - Pipeline Review, H2 2013 Research Report
M2 - Wed Feb 05, 2:35AM CST
Research and Markets (http://www.researchandmarkets.com/research/kbm7xt/methicillinsuscep) has announced the addition of the "Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections - Pipeline Review, H2 2013" report to their offering. 'Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections. Scope - A snapshot of the global therapeutic scenario for Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections. - A review of the Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Some Key Topics Covered: Introduction Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections Overview Therapeutics Development Pipeline Products for Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections - Overview Pipeline Products for Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections - Comparative Analysis brilacidin - Drug Profile LTX-109 - Drug Profile PGC Anti-MRSA - Drug Profile IMV-0123 - Drug Profile SM-295291 - Drug Profile SM-369926 - Drug Profile ASN-100 - Drug Profile Antibiotic Program - Drug Profile Drugs for Bacterial Infections - Drug Profile Human Cathelicidin LL-37 Derivatives - Drug Profile Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections - Recent Pipeline Updates Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections - Dormant Projects Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections - Discontinued Products Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections - Product Development Milestones Companies Mentioned Dainippon Sumitomo Pharma Co., Ltd. Immtech Pharmaceuticals, Inc. Cellceutix Corporation Lytix Biopharma AS PharmaIN Corporation ImmuVen, Inc. Arsanis Biosciences GmbH For more information visit http://www.researchandmarkets.com/research/kb...llinsuscep About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Market Research: Gram-Positive Bacterial Infections - Pipeline Review, H2 2013
M2 - Wed Nov 06, 2:55AM CST
Research and Markets (http://www.researchandmarkets.com/research/lxgdwn/grampositive) has announced the addition of the "Gram-Positive Bacterial Infections - Pipeline Review, H2 2013" report to their offering. 'Gram-Positive Bacterial Infections - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Gram-Positive Bacterial Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Gram-Positive Bacterial Infections. Scope - A snapshot of the global therapeutic scenario for Gram-Positive Bacterial Infections. - A review of the Gram-Positive Bacterial Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Gram-Positive Bacterial Infections pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Rib-X Pharmaceuticals, Inc. Aphios Corporation BioMarin Pharmaceutical Inc. Alchemia Limited Immtech Pharmaceuticals, Inc. Basilea Pharmaceutica Ltd. Oragenics, Inc. Dongwha Pharm Co., Ltd. Theravance, Inc. Phynova Group Ltd Novabiotics Ltd Priaxon AG ConjuGon, Inc. MicuRx Pharmaceuticals, Inc. AiCuris GmbH & Co. KG Destiny Pharma Ltd. Atox Bio Inc. Microbiotix, Inc. Cellceutix Corporation KYORIN Pharmaceutical Co., Ltd. Lytix Biopharma AS TAXIS Pharmaceuticals, Inc. Aureogen Biosciences, Inc. Cantab Biopharmaceuticals Limited For more information visit http://www.researchandmarkets.com/research/lx...ampositive About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline Review, H2 2013
M2 - Tue Oct 15, 9:04AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8fv3sr/methicillinresist) has announced the addition of the "Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline Review, H2 2013" report to their offering. 'Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections. Scope - A snapshot of the global therapeutic scenario for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections. - A review of the Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Genentech, Inc. Targeted Genetics Corporation Takeda Pharmaceutical Company Limited Piramal Healthcare Limited Rib-X Pharmaceuticals, Inc. Aphios Corporation BioMarin Pharmaceutical Inc. Cubist Pharmaceuticals, Inc. Wockhardt Limited Paratek Pharmaceuticals, Inc. Alchemia Limited Helix BioMedix, Inc. Immtech Pharmaceuticals, Inc. Lorus Therapeutics Inc Basilea Pharmaceutica Ltd. NovaBay Pharmaceuticals, Inc. Oragenics, Inc. MorphoSys AG Theravance, Inc. Galapagos NV CrystalGenomics, Inc. Phynova Group Ltd Microbio Co., Ltd. and many more... For more information visit http://www.researchandmarkets.com/research/8f...llinresist About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Malaria - Pipeline Review, H2 2013
M2 - Wed Oct 09, 6:16AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nj95jg/malaria) has announced the addition of the "Malaria - Pipeline Review, H2 2013" report to their offering. 'Malaria - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Malaria, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Malaria. Scope - A snapshot of the global therapeutic scenario for Malaria. - A review of the Malaria products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Malaria pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Malaria. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Malaria pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned Genzyme Corporation Sanofi-Aventis AstraZeneca PLC GlaxoSmithKline plc Inovio Biomedical Corporation GenVec, Inc. Novartis AG Actelion Ltd Chong Kun Dang Pharmaceutical Eisai Co., Ltd. Pfizer Inc. Ranbaxy Laboratories Limited Aduro BioTech CEL-SCI Corporation Crucell N.V. Hollis-Eden Pharmaceuticals, Inc. Immtech Pharmaceuticals, Inc. Mymetics Corporation Patrys Limited BioCryst Pharmaceuticals, Inc. IPCA Laboratories Limited Lipoxen PLC Raptor Pharmaceuticals Corp. Affitech A/S and many more... For more information visit http://www.researchandmarkets.com/research/nj95jg/malaria About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Enterococcus Faecium Infections - Pipeline Review, H2 2012
M2 - Thu Aug 01, 6:09AM CDT
Research and Markets (http://www.researchandmarkets.com/research/k929nz/enterococcus) has announced the addition of the "Enterococcus Faecium Infections - Pipeline Review, H2 2012" report to their offering. This research provides an overview of the Enterococcus Faecium Infections therapeutic pipeline. I also provides information on the therapeutic development for Enterococcus Faecium Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Enterococcus Faecium Infections. The information is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Scope - A snapshot of the global therapeutic scenario for Enterococcus Faecium Infections. - A review of the Enterococcus Faecium Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Enterococcus Faecium Infections pipeline on the basis of route of administration and molecule type. - Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress. Key Topics Covered: List of Tables List of Figures Introduction Report Coverage Enterococcus Faecium Infections Overview Therapeutics Development An Overview of Pipeline Products for Enterococcus Faecium Infections Companies Involved in Enterococcus Faecium Infections Therapeutics Development Drug Profiles with Product Descriptions and Mechanisms of Action Featured News & Press Releases Appendix Companies Mentioned: - Aquapharm Biodiscovery Limited - Ceragenix Pharmaceuticals - Immtech Pharmaceuticals - Lorus Therapeutics - MerLion Pharmaceuticals - MicuRx Pharmaceuticals, Inc - Nabi Biopharmaceuticals - Oragenics, Inc - Paratek Pharmaceuticals - Piramal Healthcare Limited - Trius Therapeutics, Inc - Wockhardt Limited For more information visit http://www.researchandmarkets.com/research/k9...terococcus
Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections - Pipeline Review, H1 2013
M2 - Wed Jun 19, 10:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5dnrjr/methicillinsuscep) has announced the addition of the "Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections - Pipeline Review, H1 2013" report to their offering. 'Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections. M Scope - A snapshot of the global therapeutic scenario for Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections. - A review of the Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections products under development by companies and unive
